U.S. SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

Form 10-KSB/A

AMENDMENT NO. 1

|ý                                       | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|--------------------------------------- | ------------------------------------------------------------------------------------
|For the fiscal year ended June 30, 2004
|o                                       | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  

Commission File Number 000-24541

CORGENIX MEDICAL CORPORATION(Name of Small Business Issuer in its charter)

|Nevada(State or other jurisdiction of
incorporation or organization)                                        |  | 93-1223466(I.R.S. Employer
Identification No.)
|----------------------------------------------------------------------------------------------------------- |  | ----------------------------------------------
|12061 Tejon Street, Westminster, Colorado 80234(Address of principal executive offices, including zip code)
|(303) 457-4345(Issuer's telephone number, including area code)                                             
|Securities registered pursuant to Section 12(b) of the Act:None                                            
|Securities registered pursuant to Section 12(g) of the Act:Common Stock, $.001 Par Value                   

Check
whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes ý    No o

Check if no disclosure of delinquent filers in response to Item 405 of Regulation S-B is contained in this form, and no disclosure will be
contained, to the best of the issuer's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to
this Form 10-KSB. ý

The issuer's revenues for its most recent fiscal year were: $5,162,924. The aggregate market value of the voting stock held by non-affiliates of the
issuer was $1,040,586 as of June 30, 2004. The number of shares of Common Stock outstanding was 5,324,818 as of October 11, 2004.

Indicate
by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the
Act) Yes o    No ý

Transitional Small Business Disclosure
Format: Yes o    No ý



---



EXPLANATORY NOTE

This amendment on Form 10-KSB/A is being filed in order to amend the disclosure in Item 8A of Corgenix Medical Corporation's (the
"Company", "Corgenix", "we" or "our") Annual Report on Form 10-KSB for the fiscal year ended June 30, 2004, as originally filed with the Securities and Exchange Commission on
October 13, 2004.

PART II

Item 8A. Controls and Procedures.

Evaluation of disclosure controls and procedures. The Company, under the supervision and with the participation of the Company's management, including its Chief
Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as required by
Rules 13a-15 and 15d-15 of the Securities Exchange Act of 1934 (the "Exchange Act")) as of the end of the period covered by this report (the "Evaluation Date"). Based
upon this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the Evaluation Date, the Company's disclosure controls and procedures were effective for the
purposes of recording, processing, summarizing and timely reporting information required to be disclosed by the Company in the reports that it files under the Exchange Act and that such information is
accumulated and communicated to the Company's management in order to allow timely decisions regarding required disclosure.

Changes
in internal controls. There have been no significant changes in the Company's internal controls or in other factors that could significantly affect the Company's disclosure
controls and procedures subsequent to the Evaluation Date, nor were there any significant deficiencies or material weaknesses in the Company's internal controls.

PART III

Item 1. Index to Exhibits

|Exhibit Number |  | Description of Exhibit                                                                            
|-------------- |  | --------------------------------------------------------------------------------------------------
|31.1           |  | Certification of Douglass T. Simpson pursuant to section 302 of the Sarbanes-Oxley Act of 2002*   
|31.2           |  | Certification of William H. Critchfield pursuant to section 302 of the Sarbanes-Oxley Act of 2002*

---

---



SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

| |  | CORGENIX MEDICAL CORPORATION
| |  | ----------------------------
| |  | By:                         
| |  | July 26, 2005               

---